Search results
Showing 1021 to 1035 of 1362 results for social care
Agenda and papers of the NICE public board meeting on 19 March 2025
Agenda and papers of the NICE public board meeting on 22 July 2025
Agenda and papers of the NICE public board meeting on 20 May 2025
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain
In development Reference number: GID-MT567 Expected publication date: TBC
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)
Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults.
Show all sections
Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.
Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.
In development Reference number: GID-TA10667 Expected publication date: TBC
In development Reference number: GID-TA10261 Expected publication date: TBC
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued Reference number: GID-TA10324
Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]
Discontinued Reference number: GID-TA10334
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.
Benralizumab for previously treated severe nasal polyps [ID1659]
In development Reference number: GID-TA10818 Expected publication date: TBC
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315